BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

BCRX 10.49 +0.43 (4.27%)
price chart
Insider Transaction Update: BioCryst Pharmaceuticals, Inc. Director Buys ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the Director of Biocryst Pharmaceuticals Inc, Hutson Nancy J, had purchased 10,000 shares in a ...
BioCryst Pharmaceuticals, Inc. Price Target Update
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): The stock price is expected to reach $ 17.83 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $24 while the lower ...
BioCryst Pharmaceuticals Receives Average Rating of "Buy" from ...  Intercooler
Best Stocks: Virtusa Corp. (NASDAQ:VRTU), BioCryst Pharmaceuticals ...  Property Mentor
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) in Spotlight
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced financial results for the fourth quarter and full year ended December 31, 2014.
Revenue Update on BioCryst Pharmaceuticals, Inc.  Ashburn Daily
Price Target Update on BioCryst Pharmaceuticals, Inc.  Bar and Graph Report
UPDATE: BioCryst Pharmaceuticals Posts Narrower-Than-Expected Q4 Loss
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) reported a narrower-than-expected loss for the fourth quarter. The Durham, North Carolina-based company posted a quarterly loss of $11.7 million, or $0.16 per share, versus a year-ago net loss of $5.4 ...
BioCryst Pharmaceuticals, Inc. Analyst Rating Update  Stafford Daily
BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results  CNNMoney
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates (BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a small biotechnology company with a market cap of $814 million. It develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases.
BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the ...  Wall Street Pit
FDA Grants Fast Track Designation for BCX4161 for the Treatment of ...  MarketWatch
BioCryst Pharmaceuticals Inc. (BCRX) is Trading Higher on Unusual Volume for ...
BioCryst Pharmaceuticals Inc. ($BCRX) experienced unusually high volume on Feb. 23, as the stock gained 3.55% to a closing price of $10.51.
Company Shares of BioCryst Pharmaceuticals, Inc. Rally 0.9%  Ashburn Daily
BioCryst Pharmaceuticals Shares Up 6.6% Following Insider Buying Activity ...  Dakota Financial News
Zacks Long Term Rating Update on BioCryst Pharmaceuticals, Inc.
As much as 9 analysts have advised buy on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) with an average broker rating of 1.56.
BioCryst Pharmaceuticals, Inc. Registers High Short Percent of Float
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) are valued at $9.98 per share. The price is 31.7% off the 52-week high and 27% above the 52-week low.
Company Update: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the application for ...
Stock Insight: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of ...